News
-
Two months after announcing the appointment of Nocion Therapeutics CEO Rick Batycky to its board, Pulmatrix has announced a deal with Nocion to look at the use of Pulmatrix’s iSPERSE particle engineering technology for development… Read more . . .
-
ATAI Life Sciences has announced a deal with US-based Neuronasal Inc. for development of intranasal N-acetylcysteine (NAC) for the treatment of mild traumatic brain injury (mTBI, or concussion). ATAI said that it expects initiation of… Read more . . .
-
According to Pulmatrix, the Lung Cancer Initiative at Johnson & Johnson will pay $7.2 million up front plus a $2 million milestone payment for an option “to access a portfolio of narrow spectrum kinase inhibitors intended for development… Read more . . .
-
CF PharmTech, which says it is developing a variety of OINDPs, announced that it has closed a Series E financing round that will be used to support development of its pipeline products. The $90 million round… Read more . . .
-
According to Savara, the FDA has granted Breakthrough Therapy designation for Molgradex inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). In June 2019, Savara announced that the Phase… Read more . . .
-
AstraZeneca has announced that its PT010 budesonide/glycopyrronium/formoterol fumarate MDI has been approved by the Chinese National Medical Products Administration for the treatment of COPD. PT010 was approved in Japan as Breztri Aerosphere in June 2019.… Read more . . .
-
According to Evoke Pharma, the company has resubmitted its 505(b)(2) for Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis. Evoke originally submitted the NDA for Gimoti in in June 2018 and announced that… Read more . . .
-
Inhaled drug developer Savara announced that it has entered into a definitive agreement for a private placement of common stock, pre-funded warrants, and milestone warrants with an expected $26.8 million in gross proceeds from sales… Read more . . .
-
CDMO MedPharm has announced the appointment of Lynn Allen as VP of Business Development, responsible for growing the business in North America. Allen has extensive experience in CDMO business development and was most recently Senior… Read more . . .
-
Finnish nanonization specialists Nanoform have filed for GMP certification with the Finnish Medicines Agency (FIMEA), the company said. In December 2018, Nanoform announced construction of a new GMP manufacturing facility in Helsinki. The company, which… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA